Tyrosine kinase inhibitors and the dawn of molecular cancer therapeutics

Annual Review of Pharmacology and Toxicology

Volumn 45, Issue , 2005, Pages 357-384

  Tibes, Raoul ^a   Trent, Jonathan ^a   Kurzrock, Razelle ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Bcr Abl; Cancer; Imatinib mesylate; Kinase; KIT

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 2; BCR ABL PROTEIN; BEVACIZUMAB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; GEFITINIB; GLUCOKINASE; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE; MIXED LINEAGE KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE C; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RAS PROTEIN; S6 KINASE; STAT PROTEIN; STEM CELL FACTOR RECEPTOR; STRESS ACTIVATED PROTEIN KINASE; TRASTUZUMAB; VASCULOTROPIN;

BREAST CANCER; CANCER INHIBITION; CHRONIC MYELOID LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; COLORECTAL CANCER; DRUG DESIGN; DRUG TARGETING; EDEMA; ENZYME INHIBITION; ENZYME INHIBITOR INTERACTION; ENZYME STRUCTURE; FATIGUE; FEVER; FLUID RETENTION; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL SYMPTOM; HEAD AND NECK CANCER; HEADACHE; HISTIOCYTOMA; HUMAN; HYPEREOSINOPHILIC SYNDROME; KIDNEY CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MAST CELL; MUSCLE CRAMP; MUSCULOSKELETAL DISEASE; MYALGIA; NAUSEA; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; RASH; REVIEW; SARCOMA; SYSTEMATIC REVIEW; THROMBOCYTOPENIA;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES;

EID: 13844316734     PISSN: 03621642     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.pharmtox.45.120403.100124     Document Type: Review

References (138)

1. Hanahan D, Weinberg RA. 2000. The hallmarks of cancer. Cell 100:57-70
2. Schlessinger J. 2000. Cell signaling by receptor tyrosine kinases. Cell 103:211-25
3. Blume-Jensen P, Hunter T. 2001. Oncogenic kinase signalling. Nature 411:355-65
4. Van Etten RA, Jackson P, Baltimore D. 1989. The mouse type IV c-abl gene product is a nuclear protein, and activation of transforming ability is associated with cytoplasmic localization. Cell 58:669-78
5. Wetzler M, Talpaz M, Van Etten RA, Hirsh-Ginsberg C, Beran M, Kurzrock R. 1993. Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation. J. Clin. Invest. 92:1925-39
6. Wetzler M, Talpaz M, Yee G, Stass SA, Van Etten RA, et al. 1995. Cell cycle-related shifts in subcellular localization of BCR: association with mitotic chromosomes and with heterochromatin. Proc. Natl. Acad. Sci. USA 92:3488-92
7. Hubbard SR, Till JH. 2000. Protein tyrosine kinase structure and function. Annu. Rev. Biochem. 69:373-98
8. Ullrich A, Schlessinger J. 1990. Signal transduction by receptors with tyrosine kinase activity. Cell 61:203-12
9. Heldin CH. 1995. Dimerization of cell surface receptors in signal transduction. Cell 80:213-23
10. Heldin CH, Westermark B. 1999. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol. Rev. 79:1283-316
11. Miller WE, Raab-Traub N. 1999. The EGFR as a target for viral oncoproteins. Trends Microbiol. 7:453-58
12. Druker BJ, Lydon NB. 2000. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J. Clin. Invest. 105:3-7
13. Manley PW, Cowan-Jacob SW, Buchdunger E, Fabbro D, Fendrich G, et al. 2002. Imatinib: a selective tyrosine kinase inhibitor. Eur. J. Cancer 38 (Suppl 5.): S19-S27
14. Savage DG, Antman KH. 2002. Imatinib mesylate-a new oral targeted therapy. New Engl. J. Med. 346:683-93
15. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, et al. 1996. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2:561-66
16. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J. 2000. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289:1857-59
17. le Coutre P, Mologni L, Cleris L, Marchesi E, Buchdunger E, et al. 1999. In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor. J. Natl. Cancer Inst. 91:163-68
18. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, et al. 2000. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J. Pharmacol. Exp. Ther. 295:139-45
19. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, et al. 2001. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344:1038-42
20. Ottmann OG, Druker BJ, Sawyers CL, Goldman JM, Reiffers J, et al. 2002. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 100:1965-71
21. Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, et al, 2002. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 99:3530-39
22. Benjamin RS, Rankin C, Fletcher CD, Demetri GD. 2003. Phase III dose-randomized study of imatinib mesylate (STI571) for GIST: Intergroup S0033 early results. Proc. Am. Soc. Clin. Oncol. 22:3271 (Abstr.)
23. Blanke CD, Joensuu H, Demetri GD, Heinrich P, von Mehren M. 2003. Long-term follow up of advanced gastrointestinal stomal tumor (GIST) patients treated with imatinib mesylate. Proc. Am. Soc. Clin. Oncol. 22:2 (Abstr.)
24. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, et al. 2002. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 347:472-80
25. Akin C, Fumo G, Yavuz AS, Lipsky PE, Neckers L, Metcalfe DD. 2004. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood 103:3222-25
26. Pardanani A, Ketterling RP, Brockman SR, Flynn HC, Paternoster SF, et al. 2003. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 102:3093-96
27. Ma Y, Zeng S, Metcalfe DD, Akin C, Dimitrijevic S, et al. 2002. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 99:1741-44
28. Pardanani A, Elliott M, Reeder T, Li CY, Baxter EJ, et al. 2003. Imatinib for systemic mast-cell disease. Lancet 362:535-36
29. Maki RG, Awan RA, Dixon RH, Jhanwar S, Antonescu CR. 2002. Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. Int. J. Cancer 100:623-26
30. Rubin BP, Schuetze SM, Eary JF, Norwood TH, Mirza S, et al. 2002. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J. Clin. Oncol. 20:3586-91
31. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, et al. 2003. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N. Engl. J. Med. 348:1201-14
32. Cortes J, Ault P, Koller C, Thomas D, Ferrajoli A, et al. 2003. Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood 101:4714-16
33. Gleich GJ, Leiferman KM, Pardanani A, Tefferi A, Butterfield JH. 2002. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet 359:1577-78
34. Pardanani A, Tefferi A. 2004. Imatinib therapy for hypereosinophilic syndrome and eosinophilia-associated myeloproliferative disorders. Leuk. Res. 28 (Suppl. 1):47-52
35. Apperley JF, Gardembas M, Melo JV, Russell-Jones R, Bain BJ, et al. 2002. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N. Engl. J. Med. 347:481-87
36. Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, et al. 2003. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N. Engl. J. Med. 349:1423-32
37. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, et al. 2003. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 348:994-1004
38. Cortes J, Giles F, O'Brien S, Thomas D, Garcia-Manero G, et al, 2003. Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha. Blood 102:83-86
39. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, et al. 2002. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N. Engl. J. Med. 346:645-52
40. Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, et al. 2002. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 99:1928-37
41. Kantarjian HM, O'Brien S, Cortes JE, Giralt SA, Rios MB, et al. 2002. Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 100:1590-95
42. Olavarria E, Ottmann OG, Deininger M, Clark RE, Bandini G, et al. 2003. Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia 17:1707-12
43. Rowley JD. 1973. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243:290-93
44. Nowell PC, Hungerford DA. 2004. A minute chromosome in human chronic granulocytic leukemia. Science 132:1497 (Abstr.)
45. Kloetzer W, Kurzrock R, Smith L, Talpaz M, Spiller M, et al. 1985. The human cellular abl gene product in the chronic myelogenous leukemia cell line K562 has an associated tyrosine protein kinase activity. Virology 140:230-38
46. Kurzrock R, Shtalrid M, Romero P, Kloetzer WS, Talpas M, et al. 1987. A novel c-abl protein product in Philadelphia-positive acute lymphoblastic leukaemia. Nature 325:631-35
47. Kurzrock R, Kantarjian HM, Druker BJ, Talpaz M. 2003. Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics. Ann. Intern. Med. 138:819-30
48. Sawyers CL. 1999. Chronic myeloid leukemia. N. Engl. J. Med. 340:1330-40
49. Garcia-Manero G, Faderl S, O'Brien S, Cortes J, Talpaz M, Kantarjian HM. 2003. Chronic myelogenous leukemia: a review and update of therapeutic strategies. Cancer 98:437-57
50. Kelliher MA, McLaughlin J, Witte ON, RosenbergN. 1990. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. Proc. Natl. Acad. Sci. USA 87:6649-53
51. Heisterkamp N, Jenster G, ten Hoeve J, Zovich D, Pattengale PK, Groffen J. 1990. Acute leukaemia in bcr/abl transgenic mice. Nature 344:251-53
52. Guerrasio A, Serra A, Gottardi E, Cilloni D, Vischia F, et al. 1997. Molecular events in chronic myeloid leukemia progression. Leukemia 11 (Suppl. 3):519-21
53. Konopka JB, Watanabe SM, Witte ON. 1984. An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity. Cell 37:1035-42
54. Davis RL, Konopka JB, Witte ON. 1985. Activation of the c-abl oncogene by viral transduction or chromosomal translocation generates altered c-abl proteins with similar in vitro kinase properties. Mol. Cell Biol. 5:204-13
55. Laurent E, Mitchell DL, Estrov Z, Lowery M, Tucker SL, et al. 2003. Impact of p210(Bcr-Abl) on ultraviolet C wavelength-induced DNA damage and repair. Clin. Cancer Res. 9:3722-30
56. Sawyers CL. 1999. Chronic myeloid leukemia. N. Engl. J. Med. 340:1330-13
57. Talpaz M, Kantarjian HM, McCredie K, Trujillo JM, Keating MJ, Gutterman JU. 1986. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. N. Engl. J. Med. 314:1065-69
58. Kantarjian H, Talpaz M, O'Brien S, Giles F, Rios MB, et al. 2003. Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer 97:2225-28
59. Kantarjian HM, Cortes J, O'Brien S, Giles FJ, Albitar M, et al. 2002. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood 99:3547-53
60. Weisberg E, Griffin JD. 2000. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood 95:3498-505
61. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, et al. 2001. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293:876-80
62. Branford S, Rudzki Z, Walsh S, Grigg A, Arthur C, et al. 2002. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 99:3472-75D
63. Hochhaus A, Kreil S, Corbin AS, La Rosee P, Muller MC, et al. 2002. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 16:2190-96
64. Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, et al. 2002. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell. 2:117-25
65. Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, Lai JL, Philippe N, et al. 2002. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 100:1014-18
66. James HA, Gibson I. 1998. The therapeutic potential of ribozymes. Blood 91:371-82
67. Wu Y, Ma G, Lu D, Lin F, Xu HJ, et al. 1999. Bcr: a negative regulator of the Bcr-Abl oncoprotein. Oncogene 18:4416-24
68. Sun X, Layton JE, Elefanty A, Lieschke GJ. 2001. Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL-expressing cells, demonstrating synergy between AG490 and STI571. Blood 97:2008-15
69. Beaupre DM, Kurzrock R. 1999. RAS and leukemia: from basic mechanisms to gene-directed therapy. J. Clin. Oncol. 17:1071-79
70. Vigneri P, Wang JY. 2001. Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nat. Med. 7:228-34
71. Kurzrock R, Talpaz M, Li N, Estrov Z. 2003. Distinct biological impact of dephosphorylation vs downregulation of p210 BCR-Abl: Implication for imatinib mesylate response and resistance. Am. Soc. Hematol. 102:264 (Abstr.)
72. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. 2004. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305:399-401
73. Gotlib J, Cools J, Malone JM III, Schrier SL, Gilliland DG, Courre SE. 2004. The FIP1L1-PDGFR{alpha} fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. Blood 103:2879-91
74. Garcia JL, Font DM, Hernandez JM, Queizan JA, Gutierrez NC, et al. 2003. Imatinib mesylate elicits positive clinical response in atypical chronic myeloid leukemia involving the platelet-derived growth factor receptor beta. Blood 102: 2699-700
75. Shimizu A, O'Brien KP, Sjoblom T, Pietras K, Buchdunger E, et al. 1999. The dermatofibrosarcoma protuberans-associated collagen type Ialpha1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB. Cancer Res. 59:3719-23
76. Sjoblom T, Shimizu A, O'Brien KP, Pietras K, Dal Cin P, et al. 2001. Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res. 61:5778-83
77. Berman J, O'Leary TJ. 2001. Gastrointestinal stromal tumor workshop. Hum. Pathol. 32:578-82
78. Duffaud F, Blay JY. 2003. Gastrointestinal stromal tumors: biology and treatment. Oncology 65:187-97
79. Blume-Jensen P, Claesson-Welsh L, Siegbahn A, Zsebo KM, Westermark B, Heldin CH. 1991. Activation of the human c-kit product by ligand-induced dimerization mediates circular actin reorganization and chemotaxis. EMBO J. 10:4121-28
80. Majumder S, Brown K, Qiu FH, Besmer P. 1988. c-kit protein, a transmembrane kinase: identification in tissues and characterization. Mol. Cell Biol. 8:4896-903
81. Turner AM, Zsebo KM, Martin F, Jacobsen FW, Bennett LG, Broudy VC. 1992. Nonhematopoietic tumor cell lines express stem cell factor and display c-kit receptors. Blood 80:374-81
82. Heinrich MC, Rubin BP, Longley BJ, Fletcher JA. 2002. Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. Hum. Pathol. 33:484-495
83. Taylor ML, Metcalfe DD. 2000. Kit signal transduction. Hematol. Oncol. Clin. North Am. 14:517-35
84. Sattler M, Salgia R. 2004. Targeting c-Kit mutations: basic science to novel therapies. Leuk. Res. 28 (Suppl. 1): 11-20
85. Rubin BP, Singer S, Tsao C, Duensing A, Lux ML, et al. 2001. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res. 61:8118-21
86. Miettinen M, Virolainen M, Maarit SR. 1995. Gastrointestinal stromal tumors-value of CD34 antigen in their identification and separation from true leiomyomas and schwannomas. Am. J. Surg. Pathol. 19:207-16
87. Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, et al. 2001. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N. Engl. J. Med. 344:1052-56
88. Verweij J, van Oosterom A, Blay JY, Judson I, Rodenhuis S, et al. 2003. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur. J. Cancer 39:2006-11
89. Choi H, Charnsangavej C, Macapinlac HA, Burgess MA, Patel SR, et al. 2003. Correlation of computerized tomography (CT) and proton emission tomography (PET) in patients with metastatic GIST treated at a single institution with imatinib mesylate. Proc. Am. Soc. Clin. Oncol. 22:3290 (Abstr.)
90. Verweij J, Casali J, Zalcberg A, LeCesne P, Reichard P, et al. 2003. Early efficacy comparison of two doses of imatinib for the treatment of advanced gastrointestinal stromal tumors (GIST): Interim results of a randomized phase III trial from the EORTC-STBSG, ISG and AG-ITG. Proc. Am. Soc. Clin. Oncol. 22:3272 (Abstr.)
91. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, et al. 2003. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol. 21:4342-49
92. Metcalfe DD, Akin C. 2001. Mastocytosis: molecular mechanisms and clinical disease heterogeneity. Leuk. Res. 25:577-82
93. Cohen MH, Williams G, Johnson JR, Duan J, Gobburu J, et al. 2002. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin. Cancer. Res. 8:935-42
94. Dagher R, Cohen M, Williams G, Rothmann M, Gobburu J, et al. 2002. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin. Cancer Res. 8:3034-38
95. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, et al. 2001. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344:1031-37
96. Trempat P, Villalva C, Laurent G, Armstrong F, Delsol G, et al. 2003. Chronic myeloproliferative disorders with rearrangement of the platelet-derived growth factor alpha receptor: a new clinical target for STI571/Glivec. Oncogene 22:5702-06
97. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, et al. 2003. Cetuximab (C225) alone or in combination with irinotecan (CPT-11) in patients with epidermal growth factor receptor (EGFR)-positive, irinotecan-refractory metastatic colorectal cancer (MCRC). Proc. Am. Soc. Clin. Oncol. 22:1012 (Abstr.)
98. Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ. 2004. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol. 22:1201-08
99. Hurwitz H, Fehrenbacher L, Cartwright T, Hainsworth W, Heim W, et al. 2003. Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): Results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC. Proc. Am. Soc. Clin. Oncol. 22:3646 (Abstr.)
100. Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, et al. 2003. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J. Clin. Oncol. 21:60-65
101. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, et al. 1989. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-12
102. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, et al. 1999. Multi-national study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 17: 2639-48
103. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, et al. 2001. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344:783-92
104. Kim ES, Yokes EE, Kies MS. 2004. Cetuximab in cancers of the lung and head & neck. Semin. Oncol. 31:61-67
105. Salomon DS, Brandt R, Ciardiello F, Normanno N. 1995. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol. 19:183-232
106. Ullrich A, Coussens L, Hayflick JS, Dull TJ, Gray A, et al. 1984. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 309:418-25
107. Carpenter G, Cohen S. 1990. Epidermal growth factor. J. Biol. Chem. 265:7709-12
108. Schlessinger J. 1988. The epidermal growth factor receptor as a multifunctional allosteric protein. Biochemistry 27: 3119-23
109. Yarden Y, Sliwkowski MX. 2001. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2:127-37
110. Arteaga CL. 2002. Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. Semin. Oncol. 29:3-9
111. Wells A. 1999. EGF receptor. Int. J. Biochem. Cell Biol. 31:637-43
112. Yarden Y. 2001. The EGFR family and its ligands in human cancer, signalling mechanisms and therapeutic opportunities. Eur. J. Cancer 37 (Suppl. 4):S3-S8
113. Shvartsman SY, Hagan MP, Yacoub A, Dent P, Wiley HS, Lauffenburger DA. 2002. Autocrine loops with positive feed-back enable context-dependent cell signaling. Am. J. Physiol. Cell Physiol. 282:C545-59
114. Grandis JR, Sok JC. 2004. Signaling through the epidermal growth factor receptor during the development of malignancy. Pharmacol. Ther. 102:37-46
115. Gullick WJ. 1991. Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. Br. Med. Bull. 47:87-98
116. Nicholson RI, Gee JM, Harper ME. 2001. EGFR and cancer prognosis. Eur. J. Cancer 37 (Suppl. 4):S9-15
117. Cohen MH, Williams GA, Sridhara R, Chen G, Pazdur R. 2003. FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist 8:303-06
118. Kies MS, Harari PM. 2002. Cetuximab (Imclone/Merck/Bristol-Myers Squibb). Curr. Opin. Investig. Drugs 3:1092-100
119. Khalil MY, Grandis JR, Shin DM. 2003. Targeting epidermal growth factor receptor: novel therapeutics in the management of cancer. Expert. Rev. Anticancer Ther. 3:367-80
120. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. 1987. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-82
121. Grunwald V, Hidalgo M. 2003. Development of the epidermal growth factor receptor inhibitor OSI-774. Semin. Oncol. 30:23-31
122. Ranson M, Mansoor W, Jayson G. 2002. ZD1839 (IRESSA): a selective EGFR-TK inhibitor. Expert. Rev. Anticancer Ther. 2: 161-68
123. Wakeling AE, Guy SP, Woodburn JR, Ashton SE, Curry BJ, et al. 2002. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res. 62:5749-54
124. Bianco C, Tortora G, Bianco R, Caputo R, Veneziani BM, et al. 2002. Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). Clin. Cancer Res. 8:3250-58
125. Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, et al. 2000. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin. Cancer Res. 6:2053-63
126. Normanno N, Campiglio M, De LA, Somenzi G, Maiello M, et al. 2002. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann. Oncol. 13:65-72
127. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, et al. 2003. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 21:2237-46
128. Sirotnak FM. 2003. Studies with ZD1839 in preclinical models. Semin. Oncol. 30: 12-20
129. Perez-Soler R CA, Huberman M. 2004. Final Results from a phase II study of erlotinib (Tarceva) monotherapy in patients with advanced non-small cell lung cancer following failure of platinum-based chemotherapy. Lung Cancer 42 (Suppl. 2):246 (Abstr.)
130. Baselga J. 2001. The EGFR as a target for anticancer therapy-focus on cetuximab. Eur. J. Cancer 37 (Suppl. 4):S16-22
131. Bergers G, Benjamin LE. 2003. Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer 3:401-10
132. Miller KD, Rugo HS, Cobleigh MA. MP-KCLI. 2002. Phase III trial of capecitabine (Xeloda) plus bevacizumab (Avastin) versus capecitabine alone in women with metastatic breast cancer previously treated with an anthracycline and taxane. Breast Cancer Res. Treat. 76 (Suppl. 1):37 (Abstr.)
133. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, et al. 2003. A randomized trial of bevacizumab, an antivascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 349:427-34
134. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosel R, et al. 2004. Gefitinib in cominbation with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J. Clin. Oncol. 22:777-84
135. Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, et al. 2004. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J. Clin. Oncol. 22:785-94
136. Basel, 26 April 2004. New cancer drug Tarceva-a breakthrough with significant survival benefit in patients with advanced lung cancer. http://www.gene.com/gene/ news/press-releases/display.do?method= detail&id=7387
137. Lynch Tomas J, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, et al. 2004. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. New Engl. J. Med. 350:2129-39
138. Hirota S, Isozaki K, Moriyama Y, Sashimoto K, Nishida T, et al. 1998. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279:577-80